Mereo Biopharma

Mereo Biopharma, established in London in 2015, specializes in acquiring and advancing late-stage drug candidates from larger pharmaceutical companies. These candidates, often overlooked due to resource constraints, target rare and specialized diseases with significant unmet medical needs. Mereo's strategy involves rapidly progressing these assets through clinical development, either by partnering or divesting them, or directly commercializing them, particularly in orphan disease indications. The company combines operational efficiency with financial resources, leveraging a unique partnership with a leading global CRO, ICON, to conduct comprehensive clinical studies. Mereo's focus is on transforming the lives of patients worldwide by developing innovative medicines that can significantly improve their quality of life.

John Richard

Head of Corporate Development and Co-Founder

1 past transactions

OncoMed Pharmaceuticals

Acquisition in 2018
OncoMed Pharmaceuticals is a biotechnology company focused on developing novel therapeutics targeting the biological pathways critical to cancer growth, resistance, recurrence, and metastasis. It specializes in monoclonal antibodies, with Navicixizumab (anti-DLL4/VEGF Bispecific) and Etigilimab (Anti-TIGIT) in clinical trials for advanced solid tumors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.